• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical ophthalmology >Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery
【24h】

Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery

机译：白内障手术期间与前房内去氧肾上腺素1.0％/酮咯酸0.3％相关的视觉效果，疗效和手术并发症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The purpose of this study was to compare visual outcomes, surgical time, and perioperative surgical complications after intracameral use of either phenylephrine/ketorolac (P/K) or epinephrine (Epi) during cataract surgery. Methods: This was a single-center, retrospective case review of patients undergoing cataract surgery from August to November 2015. Of the 641 eyes of 389 patients who underwent cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes received Epi in the irrigation solution intraoperatively. All patients received a topical nonsteroidal anti-inflammatory drug regimen (bromfenac 0.07%, nepafenac 0.3%, or ketorolac 0.5%) for 3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine 2.5% on the day of surgery. Results: Mean length of surgery (LOS) was 15.4±0.6 minutes. Although a positive correlation was noted between patient age and LOS ( p <0.001), P/K was associated with a decrease in the LOS, when controlled for age quartiles. A statistically significant lower incidence of complications (1.1%) was observed with P/K use than Epi (4.5%; p =0.018). Among surgeons who used mydriatic-assist devices more frequently, P/K use was associated with a reduction in the use of these devices ( p <0.001). When controlling for age quartile, patients of age groups 69–76 and 76–92 years who received P/K had significantly better uncorrected visual acuity at postoperative day 1 than those receiving Epi ( p =0.003). Conclusion: Intracameral use of phenylephrine 1.0%/ketorolac 0.3% during cataract surgery may be effective in maintaining mydriasis. It appears to be superior to intracameral Epi at reducing intraoperative and postoperative complications, need for pupillary dilating devices, and surgical time.
机译：目的：本研究的目的是比较白内障手术期间苯肾上腺素/酮咯酸（P / K）或肾上腺素（Epi）前房使用后的视觉结果，手术时间和围手术期手术并发症。方法：这是对2015年8月至2015年11月接受白内障手术的患者进行的单中心回顾性病例回顾。在接受白内障手术的389例患者的641眼中，有260眼接受了1.0％的去氧肾上腺素/ 0.3％的酮咯酸治疗，接受了381眼术中冲洗液中的Epi。所有患者在手术前3天接受局部非甾体类抗炎药治疗方案（溴芬酸0.07％，尼帕芬酸0.3％或酮咯酸0.5％），并在手术当天接受局部托吡卡胺1.0％，环戊酸酯1.0％和去氧肾上腺素2.5％。结果：平均手术时间（LOS）为15.4±0.6分钟。尽管注意到患者年龄与LOS之间呈正相关（p <0.001），但如果控制年龄四分位数，则P / K与LOS降低相关。观察到使用P / K的并发症发生率在统计学上显着较低（1.1％），而在Epi（4.5％; p = 0.018）下。在更频繁使用散瞳辅助设备的外科医生中，P / K的使用与这些设备的使用减少有关（p <0.001）。在控制年龄四分位数时，接受P / K的69-76岁和76-92岁年龄组的患者术后1天的未矫正视敏度明显好于接受Epi的患者（p = 0.003）。结论：白内障手术前房内使用苯肾上腺素1.0％/酮咯酸0.3％可能有效维持瞳孔散大。在减少术中和术后并发症，需要瞳孔扩张装置以及手术时间方面，它似乎优于前房内Epi。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号